Overview

* MannKind Q2 2025 rev grows 6% yr/yr, driven by higher royalties and Afrezza demand

* Company reports net income of $0.7 mln, reversing a loss from prior year

* Co submits sBLA for Afrezza in pediatric population, advancing pipeline trials

Outlook

* Company expects MNKD-201 Phase 2 trial initiation by year-end 2025

* MannKind ( MNKD ) anticipates MNKD-101 interim enrollment target by early 4Q 2025

* Company awaits Afrezza pediatric sBLA review decision in early 4Q 2025

Result Drivers

* ROYALTIES BOOST - Revenue growth driven by increased royalties from Tyvaso DPI

* AFREZZA DEMAND - Higher demand and pricing for Afrezza contributed to revenue increase

* COLLABORATION REVENUE DECLINE - Decrease in collaboration revenue due to one-time items

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net $668,000

Income

Q2 Basic

EPS

Q2 $5.30

Operatin mln

g Income

Q2 $940,000

Pretax

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for MannKind Corp ( MNKD ) is $9.00, about 55.7% above its August 5 closing price of $3.99

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)